Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

9 treatments under study, led by Subprotocol G

Research Leaders

7 sponsors active, led by UMC Utrecht

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed2
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT05374564Phase 1CompletedPrimary

Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy

NCT06763549Enrolling By Invitation

COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable

NCT01209494CompletedPrimary

An Arrhythmia Risk Stratification and Genetic Trial

Showing all 3 trials

Research Network

Common Treatments

  • Subprotocol G1
  • 18fflutemetamol1
  • Subprotocol D1
  • Subprotocol C1
  • Subprotocol H1

Active Sponsors

  • UMC Utrecht1
  • University Medical Center Goettingen1
  • KU Leuven1
  • University of Athens1
  • Peerbridge Health, Inc1

Top Investigators

Related Conditions

  • Stemi1
  • Atrial Fibrillation Af1
  • Hfpef Heart Failure With Preserved Ejection Fraction1
  • Apnea Obstructive1
  • Arrhythmia1

Activity Timeline